by mheinl | Nov 29, 2023 | Uncategorized, White Papers
Expediting breakthrough medical device reimbursement has become a recent public policy issue. This paper provides evidence of the value of faster reimbursement of new medical devices using a comprehensive dataset of past approved devices. The estimation considers the...
by mheinl | Oct 27, 2023 | Uncategorized
By Tomas Philipson October 24, 2023 More than one year ago, President Biden signed the Inflation Reduction Act (IRA) into law. “His top legislative achievement has many flaws. But by far its most damaging effects will be increased illness and death stemming from...
by mheinl | Oct 9, 2023 | White Papers
This policy brief provides a quantitative analysis of how the Inflation Reduction Act’s (IRA) policy to set prices for select small molecule drugs 9 years after FDA approval impacts innovation and patient health. Price setting under the IRA undermines existing...
by mheinl | Sep 27, 2023 | News Article
by Tomas J. Philipson in The National Review Capital Matters “The Inflation Reduction Act’s Medicare price controls create bad incentives for drug development and access. This month, the Biden administration announced the initial ten drugs, of an eventual...
by mheinl | Jun 27, 2023 | Journal
Report of the Joint Economic Committee Congress of the United States on the 2023 Economic Report of the President Republican Response (See citations on pp. 128, 129, 132, 133, 134, 145, 147, 151)
